

Ate G J Van Der Zee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3786073/publications.pdf>

Version: 2024-02-01

41
papers

2,566
citations

186265

28
h-index

276875

41
g-index

43
all docs

43
docs citations

43
times ranked

3529
citing authors

#	ARTICLE	IF	CITATIONS
1	Sentinel Node Dissection Is Safe in the Treatment of Early-Stage Vulvar Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 884-889.	1.6	684
2	European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 832-837.	2.5	149
3	HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer. <i>Genome Medicine</i> , 2015, 7, 108.	8.2	138
4	Genome-Wide Promoter Analysis Uncovers Portions of the Cancer Methylome. <i>Cancer Research</i> , 2008, 68, 2661-2670.	0.9	131
5	<i>CDM1</i> and <i>MAL</i> promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease. <i>International Journal of Cancer</i> , 2013, 133, 1293-1299.	5.1	100
6	Assessment of gene promoter hypermethylation for detection of cervical neoplasia. <i>International Journal of Cancer</i> , 2006, 119, 1908-1914.	5.1	97
7	OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma. <i>Cancer</i> , 2001, 92, 2837-2844.	4.1	94
8	Prognostic factors for local recurrence of squamous cell carcinoma of the vulva: A systematic review. <i>Gynecologic Oncology</i> , 2018, 148, 622-631.	1.4	83
9	ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors. <i>Oncogene</i> , 2018, 37, 4611-4625.	5.9	72
10	Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. <i>International Journal of Cancer</i> , 1994, 59, 607-611.	5.1	71
11	ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018, 1870, 176-184.	7.4	69
12	Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II. <i>Journal of Clinical Oncology</i> , 2021, 39, 3623-3632.	1.6	69
13	Methylation Markers for <i>CCNA1</i> and <i>C13ORF18</i> Are Strongly Associated with High-Grade Cervical Intraepithelial Neoplasia and Cervical Cancer in Cervical Scrapings. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 3000-3007.	2.5	62
14	Breaking the DNA damage response to improve cervical cancer treatment. <i>Cancer Treatment Reviews</i> , 2016, 42, 30-40.	7.7	54
15	Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions. <i>Drug Resistance Updates</i> , 2016, 24, 55-69.	14.4	52
16	First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers. <i>Molecular Therapy</i> , 2021, 29, 611-625.	8.2	48
17	Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer. <i>BMC Medicine</i> , 2017, 15, 116.	5.5	44
18	Host-cell DNA methylation patterns during high-risk HPV-induced carcinogenesis reveal a heterogeneous nature of cervical pre-cancer. <i>Epigenetics</i> , 2018, 13, 769-778.	2.7	43

#	ARTICLE	IF	CITATIONS
19	Biobanking of patient and patient-derived xenograft ovarian tumour tissue: efficient preservation with low and high fetal calf serum based methods. <i>Scientific Reports</i> , 2015, 5, 14495.	3.3	41
20	Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma. <i>Cancer Letters</i> , 2019, 461, 102-111.	7.2	40
21	Markers of fibroblast-rich tumor stroma and perivascular cells in serous ovarian cancer: Inter- and intra-patient heterogeneity and impact on survival. <i>Oncotarget</i> , 2016, 7, 18573-18584.	1.8	40
22	Functional validation of putative tumor suppressor gene <i>C13ORF18</i> in cervical cancer by Artificial Transcription Factors. <i>Molecular Oncology</i> , 2013, 7, 669-679.	4.6	39
23	DNA methylation markers as a triage test for identification of cervical lesions in a high risk human papillomavirus positive screening cohort. <i>International Journal of Cancer</i> , 2019, 144, 746-754.	5.1	37
24	Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 3928-3940.	7.0	35
25	Update on sentinel lymph node biopsy for early-stage vulvar cancer. <i>Gynecologic Oncology</i> , 2015, 138, 472-477.	1.4	34
26	Re-expression of Selected Epigenetically Silenced Candidate Tumor Suppressor Genes in Cervical Cancer by TET2-directed Demethylation. <i>Molecular Therapy</i> , 2016, 24, 536-547.	8.2	33
27	Repeat sentinel lymph node procedure in patients with recurrent vulvar squamous cell carcinoma is feasible. <i>Gynecologic Oncology</i> , 2016, 140, 415-419.	1.4	30
28	Prolonged re-expression of the hypermethylated gene <i>EPB41L3</i> using artificial transcription factors and epigenetic drugs. <i>Epigenetics</i> , 2015, 10, 384-396.	2.7	28
29	Clinical Validation of the Cervista HPV HR Test According to the International Guidelines for Human Papillomavirus Test Requirements for Cervical Cancer Screening. <i>Journal of Clinical Microbiology</i> , 2014, 52, 4391-4393.	3.9	20
30	Proteomic alterations in early stage cervical cancer. <i>Oncotarget</i> , 2018, 9, 18128-18147.	1.8	20
31	A Virosomal Immunization Strategy against Cervical Cancer and Pre-Malignant Cervical Disease. <i>Antiviral Therapy</i> , 2006, 11, 717-728.	1.0	20
32	Integrated transcriptomic and epigenomic analysis of ovarian cancer reveals epigenetically silenced GULP1. <i>Cancer Letters</i> , 2018, 433, 242-251.	7.2	16
33	Genome-wide methylome analysis using MethylCap-seq uncovers 4 hypermethylated markers with high sensitivity for both adeno- and squamous-cell cervical carcinoma. <i>Oncotarget</i> , 2016, 7, 80735-80750.	1.8	15
34	Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer. <i>PLoS ONE</i> , 2016, 11, e0165385.	2.5	13
35	DNA methylation markers as triage test for the early identification of cervical lesions in a Chinese population. <i>International Journal of Cancer</i> , 2021, 148, 1768-1777.	5.1	13
36	Comparing the Cervista HPV HR Test and Hybrid Capture 2 Assay in a Dutch Screening Population: Improved Specificity of the Cervista HPV HR Test by Changing the Cut-Off. <i>PLoS ONE</i> , 2014, 9, e101930.	2.5	11

#	ARTICLE	IF	CITATIONS
37	History and Updates of the GROINSS-V Studies. <i>Cancers</i> , 2022, 14, 1956.	3.7	8
38	Folate Receptor-Beta Has Limited Value for Fluorescent Imaging in Ovarian, Breast and Colorectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0135012.	2.5	7
39	Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene. <i>PLoS ONE</i> , 2020, 15, e0235766.	2.5	2
40	Radical vulvectomy with right gluteal and left medial thigh V-Y advancement flap reconstruction. <i>Journal of the Turkish German Gynecology Association</i> , 2021, 22, 339-342.	0.6	1
41	Trial in progress: Phase II activity trial of high-dose radiation and chemosensitization in patients with macrometastatic lymph node spread after sentinel node biopsy in vulvar cancer: Groningen International Study on Sentinel Nodes in Vulvar Cancer III (GROINSS-V III/NRG-GY024).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS5624-TPS5624.	1.6	0